Major Depressive Disorder and Bone Mass in Adolescents and Young Adults

Abstract

Depression has been associated with reduced bone mass in adults, but the mechanisms remain unclear. In addition, little is known about the association between depression and bone health during growth and development. To address this knowledge gap, we examined bone density and structure in 222 adolescents and young adults (69% females, mean±SD age: 19.0±1.5 years), enrolled within one month of starting a selective serotonin reuptake inhibitor (SSRI) or unmedicated. Psychiatric functioning was assessed with self-report and researcher-administered instruments, including the Longitudinal Interval Follow-up Evaluation for Adolescents (A-LIFE). Anthropometric and laboratory measures included dual-energy x-ray absorptiometry and peripheral quantitative computed tomography scans. Linear multivariable regression analysis tested the association between depression and bone mass, after accounting for relevant confounders. The presence of current depression was associated with a significant reduction in age-sex-height-race-specific bone mineral density (BMD) and content (BMC) of total body less head and lumbar spine. The findings varied by assessment method with self-report scales, capturing symptom severity over the prior week or two, yielding the weakest associations. Depression was also associated with reduced cortical thickness and a trend for increased endosteal circumference. In contrast, generalized anxiety disorder was not associated with bone deficits. In sum, depressive illness is associated with significantly lower bone mass in youths. Future investigations must examine whether bone recovery is possible following depression remission or whether remedial interventions are warranted to optimize bone mass in order to minimize the long-term risk of osteoporosis.

The Effect of Psychostimulants on Skeletal Health in Boys Co-Treated with Risperidone

“…19, 20 The medical and pharmacy records were reviewed to document all psychotropic treatments, including the start and stop date of each drug and its dosage. 19, 20 All dosages of psychostimulants were expressed in methylphenidate (MPH) equivalents for amphetamines (x2). 21 …”

“…Following the same protocol described previously, 18, 20 peripheral quantitative computed tomography (pQCT) scans were obtained at the 4% site of the nondominant radius (rich in trabecular bone), to estimate volumetric bone mineral density (vBMD), and at the 20% site to estimate cortical vBMD. A Stratec XCT-2000 scanner, software version 6.0 (Stratec, Inc., Pforzheim, Germany), was used.…”

Polyunsaturated fatty acid composition and childhood adversity: Independent correlates of depressive symptom persistence

“…Participants, 15 to 20 years old, who were within one month of starting a selective serotonin reuptake inhibitor (SSRI) (n=88), or who were taking no psychotropic medication (n=92), were enrolled from outpatient and inpatient clinical settings, as well as by e-mail solicitation and word of mouth, into a longitudinal observational study designed to examine the effects of SSRIs on bone mass 37 . Of those taking SSRIs, 25 (28.4%) were taking fluoxetine, 25 (28.4%) sertraline, 6 (6.8%) escitalopram and 2 (2.3%) paroxetine.…”

Sexual Functioning in Adolescents With Major Depressive Disorder

“…The parent study is a longitudinal examination of the skeletal effects of SSRIs 9 . Participants were 15 to 20 years old, enrolled within a month of beginning SSRI treatment.…”